Hemostatic powder TC-325 in Maliganant upper GI bleeding

Hemostatic powder TC-325 has emerged as a promising treatment option for malignant upper gastrointestinal bleeding (MUGIB), which is one of the most difficult types of GI bleeding to manage. MUGIB often results from cancer-related lesions that bleed heavily and are resistant to control using standard endoscopic therapy (SET). TC-325 has demonstrated clinical superiority over SET in terms of quicker and more reliable control of bleeding, and recent research has explored its cost-effectiveness as a first-line treatment in the United Kingdom.

Clinical Effectiveness of TC-325:

1. Immediate Hemostasis: TC-325 showed higher rates of immediate bleeding control compared to SET. This means that patients treated with TC-325 experienced faster stabilization of their bleeding, reducing the risk of complications.

2. Lower Rebleeding Rates: Patients who received TC-325 had fewer instances of rebleeding within a 30-day period compared to those treated with SET. This reduces the need for repeat interventions.

3. Reduced Need for Additional Procedures: Because TC-325 is more effective in controlling bleeding, it minimizes the need for further treatments such as additional endoscopic procedures, radiotherapy, surgery, or transcatheter arterial embolization. These additional interventions are often costly and carry higher risks for patients.

Cost-Effectiveness of TC-325:

1. Financial Savings: The use of TC-325 resulted in an average cost savings of £245.88 per patient compared to SET. This is due to fewer repeat procedures, hospital readmissions, and shorter hospital stays.

2. Quality-Adjusted Life Years (QALY): TC-325 provided a small but meaningful improvement in QALY (0.001), reflecting enhanced patient outcomes and quality of life.

3. Consistency Across Scenarios: Sensitivity analyses showed that TC-325 remained cost-saving and effective in 80.1% of simulated scenarios, reinforcing its reliability and robustness across varying conditions.

Advantages of TC-325:

• Reduced Rebleeding: By effectively controlling bleeding, TC-325 helps avoid the complications associated with recurrent bleeding episodes.
• Lower Overall Costs: Fewer interventions and shorter hospital stays lead to significant cost savings for healthcare systems.
• Improved Patient Outcomes: Faster bleeding control and fewer complications improve the overall quality of care and patient experience.

Implications for the UK Healthcare System:

The study used official 2023–2024 NHS cost data to ensure realistic estimates of the financial impact. With its dual benefits of clinical effectiveness and cost savings, TC-325 is recommended as a cost-effective, reliable first-line treatment for MUGIB in the UK. Its adoption could improve patient outcomes while reducing the financial burden on healthcare systems.

Conclusion:

TC-325 hemostatic powder is a groundbreaking advancement in the management of malignant upper GI bleeding. By offering superior bleeding control, fewer repeat interventions, and cost savings, TC-325 is both clinically and economically advantageous compared to standard endoscopic therapy. Its strong performance across various scenarios makes it an ideal first-line treatment for MUGIB in the UK healthcare setting.